Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology
Authors:
Open Access
- 19 November 2019
- journal article
- review article
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 45 (1) , 1-14
Abstract
Hexavalent vaccines, protecting against six diseases (diphtheria, tetanus, pertussis [DTaP], poliovirus, hepatitis B virus [HBV], and Haemophilus influenzae type b [Hib], are routinely the standard of care in Europe. The use of combined vaccines allows the reduction of number of injections and side effects, the reduction of costs, and the increase in adherence of the family to the vaccination schedule both in terms of the number of doses and timing. The safety profile, efficacy and effectiveness of hexavalent vaccines have been extensively documented in infants and children born at term, and data are accumulating in preterm infants. Hexavalent vaccines are particularly important for preterm infants, who are at increased risk for severe forms of vaccine preventable diseases. However, immunization delay has been commonly reported in this age group. All the three hexavalent vaccines currently marketed in Italy can be used in preterm infants, and recent data confirm that hexavalent vaccines have a similar or lower incidence of adverse events in preterm compared to full-term infants; this is likely due to a weaker immune system response and reduced ability to induce an inflammatory response in preterm infants. Apnoea episodes are the adverse events that can occur in the most severe preterm infants and / or with history of respiratory distress. The risk of apnoea after vaccination seems to be related to a lower gestational age and a lower birth weight, supporting the hypothesis that it represents an unspecific response of the preterm infant to different procedures. High seroprotection rates have been reported in preterm infants vaccinated with hexavalent vaccine. However, a lower gestational age seems to be associated with lower antibody titres against some vaccine antigens (e.g. HBV, Hib, poliovirus serotype 1, and pertussis), regardless of the type of hexavalent vaccine used. Waiting for large effectiveness studies, hexavalent vaccines should be administered in preterm infants according to the same schedule recommended for infants born at term, considering their chronological age and providing an adequate monitoring for cardio-respiratory events in the 48–72 h after vaccination, especially for infants at risk of recurrence of apnoea.Keywords
This publication has 55 references indexed in Scilit:
- IgG Placental Transfer in Healthy and Pathological PregnanciesJournal of Immunology Research, 2011
- Recurrent apnoea post immunisation: Informing re-immunisation policyVaccine, 2011
- Combination VaccinesJournal of Global Infectious Diseases, 2011
- Responses to a Conjugate Pneumococcal Vaccine in Preterm Infants Immunized at 2, 3, and 4 Months of AgeClinical and Vaccine Immunology, 2010
- Hepatitis B Response of Premature Infants after Primary and Booster Immunisation with a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Poliovirus/Haemophilus InfluenzaeType B VaccineInfectious Diseases in Obstetrics and Gynecology, 2010
- Very low birth weight infants have only few adverse events after timely immunizationJournal of Perinatology, 2009
- Four million neonatal deaths: counting and attribution of cause of deathPaediatric and Perinatal Epidemiology, 2008
- Antibody Persistence and Booster Vaccination During the Second and Fifth Years of Life in a Cohort of Children Who Were Born PrematurelyThe Pediatric Infectious Disease Journal, 2007
- Immunisation of premature infantsArchives of Disease in Childhood, 2006
- Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight childrenThe Journal of Pediatrics, 1996